|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The relationship of the GI microbiome, FGF19 and its carcinogenic activities in colorectal neoplasms enticed us to search for potential targets and research ideas for the clinical diagnosis and treatment of colorectal neoplasms.
|
31637718 |
2020 |
|
Cholestatic liver disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the gut-liver axis is not upregulated in preterm and term infants and that neonates with cholestatic liver disease will unlikely benefit from supplemental FGF19.
|
30122083 |
2020 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Lipid levels and body mass index values strongly correlated with FGF19 and FGFR4 levels in patients with colon adenomas.
|
30517925 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
|
30679232 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
|
30679232 |
2019 |
|
Biliary Atresia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The FGF19 protein was synthesized in BA HET, and its serum concentration was elevated.
|
30156739 |
2019 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively).
|
30334297 |
2019 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development.
|
31254596 |
2019 |
|
Hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.
|
30976983 |
2019 |
|
Psoriasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that FGF19 was highly expressed in psoriatic skin from psoriasis patients, as well as keratinocytes that were stimulated with a cocktail of cytokines (M5), which is an in vitro model of psoriasis.
|
31074061 |
2019 |
|
Reactive hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data support FGF-19 as a potential contributor to insulin-independent pathways driving postprandial hypoglycemia in PBH.
|
30976983 |
2019 |
|
Childhood Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
High activation of FGFR4 is strongly associated with the amplification of its specific ligand FGF19 in many types of solid tumors and hematologic malignancies, where it acts as an oncogene driving the cancer development and progression.
|
30634399 |
2019 |
|
Hematologic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
High activation of FGFR4 is strongly associated with the amplification of its specific ligand FGF19 in many types of solid tumors and hematologic malignancies, where it acts as an oncogene driving the cancer development and progression.
|
30634399 |
2019 |
|
Constipation - functional
|
0.010 |
Biomarker
|
disease |
BEFREE |
The new approaches to therapy include ion exchangers/transporters for functional constipation (sodium-glucose cotransporter 1, Na<sup>+</sup>/H<sup>+</sup> exchanger 3, and solute carrier family 26 member 3 inhibitors), bile acid modulators for constipation such as ileal bile acid transporter inhibitors and fibroblast growth factor 19 analog for functional constipation, and bile acid sequestrants or farnesoid X receptor agonists for functional diarrhea.
|
31460793 |
2019 |
|
Cholestasis, chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Associations of plasma CIT and FGF19 with chronic cholestasis and survival were estimated by logistic and Cox regression models.
|
31075790 |
2019 |
|
Hepatoma resectable
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study explored the potential of FGF19- and FGFR4-related biomarkers in predicting early tumour recurrence (ETR) and survival in patients with resectable hepatocellular carcinoma (HCC).
|
30698907 |
2019 |
|
Cholecystolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development.
|
31254596 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.
|
30518874 |
2019 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
These observations indicate that the FGF19/FGFR4 pathway may be involved in the development of neoplasia, and that FGF19 may be a valuable diagnostic marker for the identification of patients with colorectal adenomas.
|
30517925 |
2019 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that increased concentrations of FGF19 and FGF21 in patients with CKD may be associated with the metabolism of lipids and carbohydrates.
|
31614355 |
2019 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively).
|
30334297 |
2019 |
|
Bile acid malabsorption
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed area under the receiver operating characteristic curve (AUROC) analysis to identify the optimal cutoff C4 concentrations for the diagnosis of diarrhea attributable to bile acid malabsorption (BAD), defined as diarrhea and a serum concentration of FGF19 <60 pg/mL.
|
30448597 |
2019 |
|
Chronic intestinal failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate whether citrulline (CIT) and the enterokine fibroblast growth factor 19 (FGF19) are associated with chronic cholestasis and survival in adult CIF patients, and to develop a risk score to predict their survival.
|
31075790 |
2019 |